MX2019002468A - Composiciones de biotinato de magnesio y metodos de uso. - Google Patents

Composiciones de biotinato de magnesio y metodos de uso.

Info

Publication number
MX2019002468A
MX2019002468A MX2019002468A MX2019002468A MX2019002468A MX 2019002468 A MX2019002468 A MX 2019002468A MX 2019002468 A MX2019002468 A MX 2019002468A MX 2019002468 A MX2019002468 A MX 2019002468A MX 2019002468 A MX2019002468 A MX 2019002468A
Authority
MX
Mexico
Prior art keywords
methods
compositions
magnesium biotinate
biotin
biotinate
Prior art date
Application number
MX2019002468A
Other languages
English (en)
Inventor
R Komorowski James
J Nelson Deanna
Original Assignee
Jds Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jds Therapeutics Llc filed Critical Jds Therapeutics Llc
Publication of MX2019002468A publication Critical patent/MX2019002468A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/673—Vitamin B group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q3/00—Manicure or pedicure preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/002—Preparations for repairing the hair, e.g. hair cure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/58—Metal complex; Coordination compounds

Abstract

La presente solicitud se refiere a composiciones de biotinato de magnesio y métodos de uso; los métodos y las composiciones que se divulgan en la presente son particularmente útiles para proporcionar biotina biodisponible a los mamíferos y para tratar o prevenir los síntomas de deficiencia de biotina.
MX2019002468A 2016-09-01 2017-08-31 Composiciones de biotinato de magnesio y metodos de uso. MX2019002468A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662382438P 2016-09-01 2016-09-01
PCT/US2017/049757 WO2018045244A1 (en) 2016-09-01 2017-08-31 Magnesium biotinate compositions and methods of use

Publications (1)

Publication Number Publication Date
MX2019002468A true MX2019002468A (es) 2019-09-18

Family

ID=61301687

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019002468A MX2019002468A (es) 2016-09-01 2017-08-31 Composiciones de biotinato de magnesio y metodos de uso.

Country Status (9)

Country Link
US (2) US11938117B2 (es)
EP (1) EP3506895A4 (es)
JP (3) JP2019526638A (es)
CN (1) CN109890384A (es)
AU (2) AU2017318672B2 (es)
CA (1) CA3035584A1 (es)
GB (2) GB2568849B (es)
MX (1) MX2019002468A (es)
WO (1) WO2018045244A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170135969A1 (en) 2015-11-12 2017-05-18 Jds Therapeutics, Llc Topical arginine-silicate-inositol for wound healing
CN109890384A (zh) 2016-09-01 2019-06-14 Jds治疗有限公司 生物素镁组合物和使用方法
US11246886B2 (en) * 2018-09-06 2022-02-15 Nutrition 21, Llc Treatment of autism and autism spectrum disorders with biotin compositions
US20200155510A1 (en) * 2018-11-13 2020-05-21 Jds Therapeutics, Llc Treatment of autoimmune disorders, such as relapsing remitting multiple sclerosis and clinically isolated syndrome with biotin compositions
CN114504549B (zh) * 2022-02-24 2023-11-24 北京斯利安药业有限公司 生物素的水性凝胶剂及其制备方法和应用

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3337403A (en) 1963-09-05 1967-08-22 Hoffmann La Roche Stable and palatable pharmaceutical compositions
JPS5550863A (en) * 1978-10-11 1980-04-14 Sumitomo Chem Co Ltd Preparation of water-soluble biotin pharmaceutical
US4297349A (en) 1980-04-15 1981-10-27 Sandoz, Inc. Silicon-bearing carboxylic acids and amides
US4277488A (en) 1980-04-02 1981-07-07 Sumitomo Chemical Company, Limited Water-soluble biotin-containing preparation
DE3173855D1 (en) 1980-12-29 1986-03-27 Standard Oil Co Ohio Preparation of fluid bed-catalysts containing the mixed oxides of vanadium and phosphorus
US4385052A (en) 1981-07-20 1983-05-24 International Plant Research Institute, Inc. Use of trialkylsilyl-6-aminonicotinamides for the treatment of psoriasis
JPS6094949A (ja) * 1983-10-29 1985-05-28 Kanebo Ltd パラジメチルアミノ安息香酸多価金属塩
US4573996A (en) 1984-01-03 1986-03-04 Jonergin, Inc. Device for the administration of an active agent to the skin or mucosa
US4725427A (en) 1984-03-13 1988-02-16 Albion International, Inc. Effervescent vitamin-mineral granule preparation
JPS6125688A (ja) 1984-07-13 1986-02-04 Hitachi Plant Eng & Constr Co Ltd 無菌水製造装置の殺菌方法
US4597961A (en) 1985-01-23 1986-07-01 Etscorn Frank T Transcutaneous application of nicotine
US5288497A (en) 1985-05-01 1994-02-22 The University Of Utah Compositions of oral dissolvable medicaments
US4847082A (en) 1987-01-21 1989-07-11 Robert Sabin Method of treatment of Alzheimer's disease using phytic acid
FR2610522B1 (fr) 1987-02-06 1989-08-18 Gueyne Jean Produit therapeutique a base de derives organiques du silicium
US5288716A (en) 1987-02-18 1994-02-22 Ulrich Speck Use of pyridoxine derivatives in the prevention and treatment of hyperlipidaemia and atherosclerosis
US4839174A (en) 1987-10-05 1989-06-13 Pharmetrix Corporation Novel transdermal nicotine patch
US4943435A (en) 1987-10-05 1990-07-24 Pharmetrix Corporation Prolonged activity nicotine patch
US4908213A (en) 1989-02-21 1990-03-13 Schering Corporation Transdermal delivery of nicotine
EP0441119A3 (en) 1990-01-09 1992-10-14 Richard D. Levere The use of l-arginine in the treatment of hypertension and other vascular disorders
JPH04169528A (ja) * 1990-11-01 1992-06-17 Tanabe Seiyaku Co Ltd ビオチン噴霧乾燥製剤及びその製法
US5250569A (en) 1991-04-22 1993-10-05 Godfrey Science & Design, Inc. Amino acid flavorings of aluminum astringent for oral use
US5166168A (en) * 1991-05-24 1992-11-24 Stiefel Laboratories, Inc. Topical biotin compositions and method of use
US5679337A (en) 1991-06-14 1997-10-21 Professional Pharmaceutical, Inc. Method and composition for topical treatment of Aphthous stomatitis histamine using phosphate as active ingredient
ES2153362T3 (es) 1991-08-26 2001-03-01 Abbott Lab Composiciones y procedimientos de administracion sublingual o bucal de agentes terapeuticos.
JP2636118B2 (ja) 1991-09-10 1997-07-30 三省製薬株式会社 育毛剤
IT1254045B (it) 1991-12-31 1995-09-06 Lifegroup Spa Derivati idrosolubili della biotina e relative composizioni terapeutiche
US5840881A (en) 1992-11-27 1998-11-24 Takeda Chemical Industries, Ltd. Composition containing a water-insoluble or slightly water-soluble compound with enhanced water-solubility
US5549906A (en) 1993-07-26 1996-08-27 Pharmacia Ab Nicotine lozenge and therapeutic method for smoking cessation
US5622980A (en) 1993-08-17 1997-04-22 Applied Analytical Industries, Inc. Oral compositions of H2-antagonists
TW282398B (es) 1993-12-22 1996-08-01 Bristol Myers Squibb Co
CN1073119C (zh) 1994-05-18 2001-10-17 吸入治疗系统公司 干扰素干粉配方的方法及组合物
FI95441C (fi) 1994-05-31 1996-02-12 Leiras Oy Inhalointilaitteen lääkeainekammio
US5804203A (en) 1994-12-21 1998-09-08 Cosmederm Technologies Topical product formulations containing strontium for reducing skin irritation
US5612053A (en) 1995-04-07 1997-03-18 Edward Mendell Co., Inc. Controlled release insufflation carrier for medicaments
US5626884A (en) * 1995-08-18 1997-05-06 Lockett; Curtis G. Treatment of sickle cell disease
US5763496A (en) 1995-11-27 1998-06-09 The Research Foundation Of State University Of New York Prevention of atherosclerosis using NADPH oxidase inhibitors
ES2216418T3 (es) 1995-12-07 2004-10-16 Jago Research Ag Boquilla para un inhalador para la administracion de varias dosis de un polvo seco farmacologico.
FR2745498A1 (fr) 1996-02-29 1997-09-05 Giroux Jean Marc Composition pur augmenter conjointement la tolerance biologique et l'efficacite amincissante des produits hyperproteines hypocaloriques destines au traitement de l'obesite
US5871010A (en) 1996-06-10 1999-02-16 Sarnoff Corporation Inhaler apparatus with modified surfaces for enhanced release of dry powders
GB9626233D0 (en) 1996-12-18 1997-02-05 Chawla Brinda P S Medicament packaging and deliveery device
PE71699A1 (es) * 1997-02-07 1999-08-03 Sepracor Inc Composicion farmaceutica de descarboetoxiloratadina sin lactosa, no higroscopica y anhidra
US5707970A (en) 1997-02-12 1998-01-13 Nutrition 21 Arginine silicate complex and use thereof
US7629384B2 (en) 1997-09-17 2009-12-08 Strategic Science & Technologies, Llc Topical delivery of L-arginine to cause beneficial effects
US6207713B1 (en) 1997-09-17 2001-03-27 Eric T. Fossel Topical and oral delivery of arginine to cause beneficial effects
US7914814B2 (en) 1997-09-17 2011-03-29 Strategic Science & Technologies, Llc Topical delivery of arginine of cause beneficial effects
US20020068365A1 (en) 1998-07-28 2002-06-06 Eric H. Kuhrts Controlled release nitric oxide producing agents
US6472378B2 (en) * 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
DE19903241A1 (de) 1999-01-28 2000-08-03 Merck Patent Gmbh Galenische Formulierung
US6143786A (en) 1999-02-02 2000-11-07 Novartis Nutrition Ag Oral arginine and insulin secretion
JP2001181211A (ja) * 1999-12-24 2001-07-03 Sumitomo Chem Co Ltd 水溶性ビタミン粉剤
UA77660C2 (en) 2000-10-03 2007-01-15 Compositions and methods for reducing plasma lipoprotein a level in human
US6630158B2 (en) 2000-10-31 2003-10-07 Stiefel Laboratories, Inc. Dietary supplement composition and method for improving and maintaining healthy skin
JP3907964B2 (ja) 2001-04-25 2007-04-18 株式会社 伊藤園 精神疲労軽減組成物、集中力維持増強組成物及び精神的活力維持増強組成物
US6916238B2 (en) 2001-07-10 2005-07-12 David J. Korman Canopy air delivery system
EP1446104B2 (en) 2001-11-01 2011-08-03 Novartis AG Spray drying methods
RU2278659C9 (ru) 2002-02-01 2007-02-20 Пфайзер Продактс Инк. Способ получения гомогенных, высушенных распылением твердых аморфных дисперсий лекарственного средства с использованием модифицированной установки сушки распылением
DE10205190B4 (de) 2002-02-08 2017-06-08 Beiersdorf Ag 2-Methyl-1,3-propandiol haltige Zubereitungen
US6709868B2 (en) 2002-05-20 2004-03-23 Portascience Inc. Method and apparatus for measuring white blood cell count
JP2004099599A (ja) 2002-07-19 2004-04-02 Ajinomoto Co Inc 経口アミノ酸育毛剤および抜毛防止剤、ならびにそれらを使用する育発毛方法および抜毛防止法
WO2004017913A2 (en) 2002-08-22 2004-03-04 Nutrition 21, Inc. Arginine silicate inositol complex and use thereof
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
US7238373B2 (en) * 2003-04-04 2007-07-03 Nutritox Llc Nutritional supplement
US6803456B1 (en) 2003-08-13 2004-10-12 Rutherford Chemicals Llc Process for the production of arginine-silicate complex
US20050048012A1 (en) * 2003-08-26 2005-03-03 Roland Jermann Use of biotin or a biotin derivative for skin lightening purposes and for the treatment of senile lentigines
US20060020007A1 (en) * 2004-07-26 2006-01-26 Roger Berlin Compositions containing policosanol and biotin and their pharmaceutical uses
US20060115555A1 (en) 2004-12-01 2006-06-01 Foulger Sidney W Nutritional supplements containing xanthone extracts
US8377421B2 (en) 2005-11-07 2013-02-19 Martin S. Giniger Tooth glossing or finishing compositions for oral care
WO2007013655A1 (ja) * 2005-07-29 2007-02-01 Nof Corporation 食品添加用金属石鹸およびその製造方法
US20070116831A1 (en) 2005-11-23 2007-05-24 The Coca-Cola Company Dental Composition with High-Potency Sweetener
EP1973557A4 (en) * 2005-12-13 2010-03-03 Harkness Pharmaceuticals Inc NON-HYGROSCOPIC COMPOSITIONS OF ENTEROSTATIN
US20070292493A1 (en) 2006-06-15 2007-12-20 Brierre Barbara T Pharmaceutical composition and method for the transdermal delivery of calcium
US8796282B2 (en) * 2007-03-28 2014-08-05 Case Western Reserve University Method of treating dermatological disorders
WO2009051609A1 (en) 2007-10-19 2009-04-23 Pardee Joel D Metabolic enhancement therapy
CA2702630C (en) * 2007-11-08 2017-11-21 Biogen Idec Ma Inc. Use of lingo-4 antagonists in the treatment of conditions involving demyelination
EP2410981B2 (en) 2009-03-26 2020-02-26 Pulmatrix Operating Company, Inc. Dry powder formulations and methods for treating pulmonary diseases
FR2993780B1 (fr) * 2012-07-26 2015-02-13 Assist Publ Hopitaux De Paris Methode de traitement de la sclerose en plaque
WO2011161421A1 (en) 2010-06-24 2011-12-29 Cipla Limited Salts and polymorphs of dexrabeprazole
WO2012058635A1 (en) 2010-10-29 2012-05-03 Life Technologies Corporation Biotin derivatives
US9717929B2 (en) 2010-12-07 2017-08-01 Colgate-Palmolive Company Dentifrice compositions containing calcium silicate and a basic amino acid
JP5261620B2 (ja) * 2011-01-21 2013-08-14 京子 遠藤 脱毛症治療剤
AU2012271068A1 (en) 2011-06-03 2013-12-19 Transition Therapeutics Ireland Limited Scyllo-inositol for the treatment of behavioral and psychiatric disorders
US20130101569A1 (en) * 2011-10-15 2013-04-25 Anthony R. Weston Hair growth stimulant
KR101373246B1 (ko) 2011-12-29 2014-03-12 연세대학교 산학협력단 Ｐｇｅ2 합성 억제제를 포함하는 안구 통증 치료용 약학 조성물
US20130296390A1 (en) * 2012-05-07 2013-11-07 Biolink Life Sciences, Inc. Method and compositions for enhancing the safety of orally administered magnesium alpha-lipoate
EP2805730A1 (en) 2013-05-21 2014-11-26 Bergen Teknologioverforing AS Nitric oxide donor for the treatment of chronic fatigue syndrome
US20160081959A1 (en) 2014-09-24 2016-03-24 Glanbia Plc Method of using arginine silicate inositol complex for wound healing or repair
US11191735B2 (en) 2015-03-13 2021-12-07 Nutrition 21, Llc Arginine silicate for periodontal disease
US20170000809A1 (en) 2015-06-30 2017-01-05 Jds Therapeutics, Llc Arginine silicate inositol for improving cognitive function
US20170348235A1 (en) 2015-09-16 2017-12-07 Corr-Jensen, Inc. Multi-phase release of sports nutrition and energy drink compositions utilizing lipid particulates
US20170135969A1 (en) 2015-11-12 2017-05-18 Jds Therapeutics, Llc Topical arginine-silicate-inositol for wound healing
CN109890384A (zh) 2016-09-01 2019-06-14 Jds治疗有限公司 生物素镁组合物和使用方法
WO2018076108A1 (en) 2016-10-25 2018-05-03 Uti Limited Partnership Treatment for progressive multiple sclerosis
US11246886B2 (en) 2018-09-06 2022-02-15 Nutrition 21, Llc Treatment of autism and autism spectrum disorders with biotin compositions
EP3873331A4 (en) 2018-11-02 2022-08-24 Nutrition 21, LLC COMPOSITIONS CONTAINING INOSITOL-STABILIZED ARGININE SILICATE COMPLEXES AND INOSITOL FOR IMPROVING COGNITIVE FUNCTIONING IN VIDEO GAMES
US20200155510A1 (en) 2018-11-13 2020-05-21 Jds Therapeutics, Llc Treatment of autoimmune disorders, such as relapsing remitting multiple sclerosis and clinically isolated syndrome with biotin compositions
MX2019011848A (es) 2019-09-25 2021-03-26 Victor Manuel Perez Rodriguez Loción y tónico para cabello, cuero cabelludo y piel.
WO2023164272A1 (en) 2022-02-28 2023-08-31 Nutrition21, LLC Compositions comprising an active ingredient mixture comprising silicon and biotin and methods of use

Also Published As

Publication number Publication date
GB2600888A (en) 2022-05-11
WO2018045244A1 (en) 2018-03-08
JP2023065413A (ja) 2023-05-12
US20210100776A1 (en) 2021-04-08
JP2022023868A (ja) 2022-02-08
CA3035584A1 (en) 2018-03-08
GB2568849B (en) 2022-08-10
GB2568849A (en) 2019-05-29
US20180071264A1 (en) 2018-03-15
AU2017318672A1 (en) 2019-03-21
GB2600888B (en) 2022-08-10
CN109890384A (zh) 2019-06-14
JP2019526638A (ja) 2019-09-19
AU2022204008A1 (en) 2022-07-07
GB202202160D0 (en) 2022-04-06
US11938117B2 (en) 2024-03-26
AU2017318672B2 (en) 2022-03-10
US11931342B2 (en) 2024-03-19
GB201904540D0 (en) 2019-05-15
EP3506895A4 (en) 2020-04-15
EP3506895A1 (en) 2019-07-10

Similar Documents

Publication Publication Date Title
GB2568849A (en) Magnesium biotinate compositions and methods of use
PH12018501065A1 (en) Compounds and compositions useful for treating disorders related to ntrk
MX2018012016A (es) Compuestos biciclicos.
MX2016004927A (es) Composiciones utiles para tratar trastornos relacionados con kit.
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
MX2021011946A (es) Composiciones de inh-c1 y metodos para la prevencion y el tratamiento de trastornos asociados con la deficiencia del inhibidor de c1 esterasa.
SG10201908028SA (en) Cyclopropylamines as lsd1 inhibitors
GEP20207151B (en) Agents, Uses and Methods for the Treatment of Synucleinopathy
WO2016134335A3 (en) Pvrig polypeptides and methods of treatment
PH12015502048A1 (en) Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same
MX2015011898A (es) Compuestos de pirazolo y usos de los mismos.
MX2018006632A (es) Inhibidores biciclicos de peptidilarginina deiminasa 4 (pad4).
AU2016263598A8 (en) Methods and kits for treating depression
AU2017317563A8 (en) Detergent compositions comprising xanthan lyase variants I
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
MX2018006700A (es) Inhibidores aza-bencimidazol de peptidilarginina desiminasa (pad4).
MX2020002852A (es) Tratamiento mejorado de dermatitis atopica con tradipitant.
PH12016500495A1 (en) Compositions for the treatment of hypertension and/or fibrosis
MX2017006019A (es) Apilimod para uso en el tratamiento de melanoma.
PH12019500479A1 (en) Compositions for treating dementia
MX2021008225A (es) Composiciones y metodos para tratamiento de crecimiento celular anormal.
MY174711A (en) Novel anti-fc-gamma receptor iib antibodies and uses thereof
MX2018007468A (es) Composiciones de colageno 7 y metodos para usar las mismas.
PH12019500180A1 (en) Compositions for the treatment of pulmonary fibrosis